From Financialpost · · 1m 10s
ME Therapeutics Extends CD22 Nanobody Option Agreement
ME Therapeutics extends option to license Canadian nanobody for cancer therapy until February 2027.
In brief
ME Therapeutics extends option to license Canadian nanobody for cancer therapy until February 2027. ME Therapeutics extends option agreement to license National Research Council of Canada's CD22 nanobody for CAR therapy until February 10, 2027. Originally reported by Financialpost.
ME Therapeutics extends option agreement
ME Therapeutics Holdings Inc. extends option to license National Research Council of Canada's CD22 nanobody for CAR therapy.
Option exercisable until February 10, 2027
The option to license the CD22 binder is now exercisable until february 10 2027.
Company focuses on in vivo CAR program
ME Therapeutics will continue developing the cd22 nanobody as part of its in vivo car program.
Publicly listed biotech in Vancouver
ME Therapeutics is a publicly listed biotechnology company based in vancouver focused on developing novel therapeutics.
CD22 nanobody for cancer treatment
The cd22 nanobody is designed to reprogramme immune cells in vivo to reshape the tumour microenvironment and kill cancer cells.
Option agreement extension details
All other terms remain the same under the extended option agreement for the cd22 nanobody asset.
The big picture
ME Therapeutics extends option agreement to license National Research Council of Canada's CD22 nanobody for CAR therapy until February 10, 2027.
